

Listing of all claims as amended

5 1.(ORIGINAL) A peptide selected from the group having the formulae:

$R_1-A^0-A^1-A^2-\text{Asp-Ala-A}^5-A^6-\text{Thr-A}^8-A^9-A^{10}-A^{11}-A^{12}-\text{Val-Leu-A}^{15}-A^{16}-\text{Leu-Ser-A}^{19}-A^{20}-A^{21}-A^{22}-\text{Leu-Gln-Asp-Ile-A}^{27}-A^{28}-A^{29}-A^{30}-R_2$

wherein R_1 is a member of the group consisting of a) PhAc, Hca, Dat, IndAc, Ipa, 1-Nac, 2-Nac, 1-Npr, 2-Npr, Ibu; $CH_3(CH_2)_nCO$, or $HOOC(CH_2)_nCO$, where n is an integer from 2 to 20, 10 and b) any other straight chain, branch chain, saturated, unsaturated or poly unsaturated aliphatic carboxyl group of 2-30 carbon atoms and any carbocyclic or heterocyclic aromatic carboxyl group of 3-8 carbon atoms containing at least one atom of the group S, N, and O in the heterocyclic ring.

A^0 is Phe, D-Phe, Arg, D-Arg, or a carbon-nitrogen single bond,

A^1 is Tyr or His,

15 A^2 is D-Arg or D-Cit,

A^5 is Ile or Val,

A^6 is Phe, Tyr, Nal, or Phe(Y), in which $Y=F, Cl, Br, or I$,

A^8 is Asn, D-Asn, Cit, D-Cit, Gln, D-Gln, Ser, D-Ser, Thr, D-Thr, Ala, D-Ala, Abu, D-Abu, or Aib,

A^9 is His, D-His, Amp, D-Amp, Gup, or D-Gup,

20 A^{10} is Tyr, Tyr(Et), Tyr(Me); Phe(Y), in which $Y=H, F, Cl, Br, or I$; Amp, His, Cha, Chg, Bpa, Dip, Trp, Trp(For), Tpi, 1-Nal, 2-Nal, 3-Pal, 4-Pal, Phe(NH_2), or Phe(NO_2).

A^{11} is His, D-His, Arg, D-Arg, Cit, Har, D-Har, Amp, D-Amp, Gup, or D-Gup,

A^{12} is Lys, D-Lys, Orn, D-Orn, Har, D-Har, Cit, D-Cit, Nle, or Ala,

A^{15} is Gly, Ala, Abu, Aib, Nle, Gln, Cit, or His,

25 A^{16} is Gln or Arg,

A^{19} is Ala or Abu,

A^{20} is His, D-His, Arg, D-Arg, or Cit,

A^{21} is Lys, D-Lys, Orn, D-Orn, Cit, or D-Cit,

A^{22} is Leu, Ala or Aib,

30 A^{27} is Met, Leu, Nle, Abu, or D-Arg,

A^{28} is Arg, D-Arg, Har, D-Har, Ser, Asn, Asp, Ala, Abu, or Cit,

A^{29} is Arg, D-Arg, Har, D-Har, Cit, D-Cit, or Agm,

A^{30} is Arg, D-Arg, Har, D-Har, Cit, D-Cit, Agm, or is a carbon-nitrogen or carbon-oxygen single bond,

35 R_2 is $-NH_2, -NH-NH_2, -NH-OH, -NHR_3, -NR_3R_4, -OH, or -OR_3$, in which R_3 and R_4 are any of C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkinyl, C_{7-18} phenylalkyl, $-C_6H_5$, or $-CH(C_6H_5)_2$; provided that if A^{29} is Agm then A^{30} and R_2 are absent, and if A^{30} is Agm then R_2 is absent, and pharmaceutically acceptable salts thereof.

2. (ORIGINAL) The compound of claim 1 wherein one or both of A^{11} and A^{20} are other than 40 Arg, D-Arg, or Cit.

3. (ORIGINAL) A compound of claim 1 selected from the group consisting of:

5 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 67

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 68

10

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, His⁸, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 69

[CH₃(CH₂)₈CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 70

[HOOC(CH₂)₈CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 71

20 [HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 72

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 73

25

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 74

[1-Nac-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 75

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 76

35 [HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 77

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 78

40

4

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸,
Har²⁹]hGH-RH(1-29)NH₂ Peptide 79

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸,
5 Har²⁹]hGH-RH(1-29)NH₂ Peptide 80

[HOOC(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸,
Har²⁹]hGH-RH(1-29)NH₂ Peptide 81

10 [HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸,
Har²⁹]hGH-RH(1-29)NH₂ Peptide 82

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸,
Har²⁹]hGH-RH(1-29)NH₂ Peptide 86

15

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸,
Har²⁹]hGH-RH(1-29)NH₂ Peptide 87

20 [HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸,
Har²⁹]hGH-RH(1-29)NH₂ Peptide 88

[HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸,
Har²⁹]hGH-RH(1-29)NH₂ Peptide 89

25 [1-Nac-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-
29)NH₂ Peptide 91

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-
RH(1-29)NH₂ Peptide 92

30

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Cit¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 93

35 [CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, His¹⁵, His²⁰, Nle²⁷, D-Arg²⁸,
Har²⁹]hGH-RH(1-29)NH₂ Peptide 94

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Om¹², Abu¹⁵, Om²¹, Nle²⁷, D-
Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 95

5

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 96

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, 5 Har²⁹]hGH-RH(1-29)NHEt Peptide 97

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 98

10 [CH₃(CH₂)₁₀CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 99

[Hca -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 100

15

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHMe Peptide 101

20 [HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 102

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 103

25 [CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 104

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 105

30

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 106

35 [HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 107

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 108

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 109

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹,
5 Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 110

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷,
D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 111

10 [CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹,
Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 112

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹,
Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 113

15

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-
Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 114

20 [CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹,
Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 115

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹,
Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 116

25 [HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰,
Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 117

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷,
D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 118

30

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹,
Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 119

35 [HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹,
Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 120

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰,
Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 121

40

4. (ORIGINAL) A compound of claim 3 selected from the group consisting of:

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁸, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 67

5

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, His⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 69

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁸, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 70

[HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁸, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 72

15

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸,
Har²⁹]hGH-RH(1-29)NH₂
Peptide 76

[HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸,
Har²⁹]hGH-RH(1-29)NH₂
Peptide 77

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸,
Har²⁹]hGH-RH(1-29)NH₂
Peptide 79

25 [CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸,
Har²⁹]hGH-RH(1-29)NH₂
Peptide 80

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸,
Har²⁹]hGH-RH(1-29)NH₂
Peptide 86

30

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, Orn²¹, Nle²⁷, D-
Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 95

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷,
35 D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 96

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸,
Har²⁹]hGH-RH(1-29)NHEt
Peptide 97

40 5. (ORIGINAL) A compound selected from the group consisting of:

[CH₃(CH₂)₄CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 2

5 [HOOC(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 3

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 4

10

[HOOC(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 5

15 [CH₃(CH₂)₈CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 6

[HOOC(CH₂)₈CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 7

20 [CH₃(CH₂)₁₀CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 8

[HOOC(CH₂)₁₀CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 9

25

[CH₃(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 10

30 [HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 11

[CH₃(CH₂)₁₄CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 12

35 [HOOC(CH₂)₁₄CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 13

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂
Peptide 14

40

9

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂
Peptide 15

5 [CH₃(CH₂)₁₄CO-Phe⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 16

[CH₃(CH₂)₁₄CO-D-Phe⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 17

10 [PhAc-Arg⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 18

15 [PhAc-D-Arg⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 19

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 21

20 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Cit⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 22

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Arg⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂
Peptide 23

25 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Cit⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂
Peptide 24

[HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Cit⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 25

30 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, D-Ala⁸, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 26

35 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Abu⁸, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 27

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂
Peptide 28

10

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Amp¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 30

5 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Amp¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 31

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, His¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 32

10 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Cha¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 33

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tpi¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 34

15 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, 2-Nal¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 35

20 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Dip¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 36

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Phe(pNH₂)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 37

25 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Trp¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 38

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Phe(pNO₂)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 39

30 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, 3-Pal¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 40

35 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Et)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 41

[PhAc-His¹, D-Arg², Tyr⁶, Har⁹, Bpa¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 42

11

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Har¹², Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 43

5 [Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt
Peptide 45

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt
Peptide 46

10 [Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt
Peptide 47

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt
Peptide 48

15 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Aib¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt
Peptide 49

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Orn¹², Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-
20 29)NHEt
Peptide 50

[Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Agm²⁹]hGH-RH(1-29)
Peptide 51

25 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Agm²⁹]hGH-RH(1-29)
Peptide 52

[Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Har³⁰]hGH-RH(1-
30)NH₂
Peptide 53

30 [Dat-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Har³⁰]hGH-RH(1-30)NH₂
Peptide 54

35 [Ipa-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Har³⁰]hGH-RH(1-30)NH₂
Peptide 55

[Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Har³⁰]hGH-RH(1-
30)NHEt
Peptide 56

12

[Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, D-Arg²⁹, Har³⁰]hGH-RH(1-30)NH₂ Peptide 57

[Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, D-Arg³⁰]hGH-RH(1-30)NH₂ Peptide 58

[Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Agm³⁰]hGH-RH(1-30) Peptide 59

10 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Agm³⁰]hGH-RH(1-30) Peptide 60

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 62

15

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Har¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 63

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Amp¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-20 29)NH₂ Peptide 64

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Cit¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 65

25 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 84

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 85

30

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Cit¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 90

6. (ORIGINAL) A peptide of claim 5 selected from the group consisting of:

35 [CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 4

[HOOC(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 5

40

13

[HOOC(CH₂)₈CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 7

5 [HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 11

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Cit⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 22

10 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, 2-Nal¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 35

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Dip¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 36

15 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Phe(pNO₂)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 39

20 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Et)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 41

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 62

25 7. (ORIGINAL) A peptide of claim 5 selected from the group consisting of:

[CH₃(CH₂)₈CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 4

30 [HOOC(CH₂)₈CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 7

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 21

35 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Amp¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 30

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Amp¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 31

40

14

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Phe(pNH₂)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 37

5 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Et)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 41

10 [PhAc-His¹, D-Arg², Tyr⁶, Har⁹, Bpa¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 42

15 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-
29)NH₂ Peptide 62

20 8-15 (CANCELLED)

16. The method of suppressing IGF-I or IGF-II levels in the tumor tissue of a patient having
a cancer carrying receptors for IGF-I by administering to said patient a suppressively effective
amount of a compound of claim 1, any of claims 1, or 5.

17. The method of suppressing VEGF levels in the tumor tissue of a patient having a
cancer by administering to said patient a suppressively effective amount of a compound of claim 1
any of claims 1, or 5.

25 18. The method of suppressing levels of IGF-I in a patient in need of same by
administering to said patient a suppressively effective amount of a compound of claim 1, any of
claims 1, or 5.

19. The method of suppressing serum IGF-I levels in a patient having a cancer carrying
receptors for IGF-I by administering to said patient a suppressively effective amount of a
compound of claim 1, any of claims 1, or 5.

30 20. The method of suppressing GH levels in a patient having a cancer carrying receptors
for IGF-I or GH by administering to said patient a suppressively effective amount of a compound
of claim 1, any of claims 1, or 5.

35 21. The method of the treatment of a patient having a cancer carrying receptors for GH-RH
by administering to said patient an amount of a compound of claim 1 any of claims 1, or 5 effective
to block said GH-RH receptors

40 22. A pharmacologically administrable composition for the suppression of levels of GH in
a patient consisting essentially of a compound of claim 1, or 5 and a pharmacologically acceptable
carrier.

15

23. A pharmacologically administrable composition for the suppression of -IGF-I or IGF-II levels in the tumor tissue of a patient having a cancer carrying receptors for IGF-I consisting essentially of a compound of claim 1-~~or 5~~ and a pharmacologically acceptable carrier

5

24. A pharmacologically administrable composition for the suppression of VEGF levels in the tumor tissue of a patient having a cancer consisting essentially of a compound of claim 1-~~or 5~~ and a pharmacologically acceptable carrier.

10

25. A pharmacologically administrable composition for the suppression of levels of IGF-I in a patient consisting essentially of a compound of claim 1-~~or 5~~ and a pharmacologically acceptable carrier.

15

26. A pharmacologically administrable composition for the suppression of GH levels in a patient having a cancer carrying receptors for IGF-I or GH consisting essentially of a compound of claim 1, ~~or 5~~ a pharmacologically acceptable carrier.

20

27. A pharmacologically administrable composition for the suppression of IGF-I levels in a patient having a cancer carrying receptors for IGF-I consisting essentially of a compound of claim 1-~~or 5~~ and a pharmacologically acceptable carrier.

28. A pharmacologically administrable composition for blocking receptors for GH-RH in a patient having a cancer carrying receptors for GH-RH consisting essentially of a compound of claim 1-~~or 5~~ and a pharmacologically acceptable carrier.